Literature DB >> 24213770

Precompetitive consortia in biomedicine--how are we doing?

Barbara Mittleman1, Garry Neil, Joel Cutcher-Gershenfeld.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24213770     DOI： 10.1038/nbt.2731

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

2.  Open science is a research accelerator.

Authors:  Michael Woelfle; Piero Olliaro; Matthew H Todd
Journal:  Nat Chem       Date:  2011-09-23       Impact factor: 24.427

3.  Crowd sourcing in drug discovery.

Authors:  Monika Lessl; Justin S Bryans; Duncan Richards; Khusru Asadullah
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

4.  Alternative business models for drug discovery.

Authors:  Barry A Bunin; Sean Ekins
Journal:  Drug Discov Today       Date:  2011-07-02       Impact factor: 7.851

Review 5.  Can open-source drug R&D repower pharmaceutical innovation?

Authors:  B Munos
Journal:  Clin Pharmacol Ther       Date:  2010-05       Impact factor: 6.875

6.  Prepublication data sharing.

Authors:  Ewan Birney; Thomas J Hudson; Eric D Green; Chris Gunter; Sean Eddy; Jane Rogers; Jennifer R Harris; S Dusko Ehrlich; Rolf Apweiler; Christopher P Austin; Lisa Berglund; Martin Bobrow; Chas Bountra; Anthony J Brookes; Anne Cambon-Thomsen; Nigel P Carter; Rex L Chisholm; Jorge L Contreras; Robert M Cooke; William L Crosby; Ken Dewar; Richard Durbin; Stephanie O M Dyke; Joseph R Ecker; Khaled El Emam; Lars Feuk; Stacey B Gabriel; John Gallacher; William M Gelbart; Antoni Granell; Francisco Guarner; Tim Hubbard; Scott A Jackson; Jennifer L Jennings; Yann Joly; Steven M Jones; Jane Kaye; Karen L Kennedy; Bartha Maria Knoppers; Nikos C Kyrpides; William W Lowrance; Jingchu Luo; John J MacKay; Luis Martín-Rivera; W Richard McCombie; John D McPherson; Linda Miller; Webb Miller; Don Moerman; Vincent Mooser; Cynthia C Morton; James M Ostell; B F Francis Ouellette; Julian Parkhill; Parminder S Raina; Christopher Rawlings; Steven E Scherer; Stephen W Scherer; Paul N Schofield; Christoph W Sensen; Victoria C Stodden; Michael R Sussman; Toshihiro Tanaka; Janet Thornton; Tatsuhiko Tsunoda; David Valle; Eero I Vuorio; Neil M Walker; Susan Wallace; George Weinstock; William B Whitman; Kim C Worley; Cathy Wu; Jiayan Wu; Jun Yu
Journal:  Nature       Date:  2009-09-10       Impact factor: 49.962

7.  Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors.

Authors:  J A Wagner; E C Wright; M M Ennis; M Prince; J Kochan; D J R Nunez; B Schneider; M-D Wang; Y Chen; S Ghosh; B J Musser; M T Vassileva
Journal:  Clin Pharmacol Ther       Date:  2009-06-24       Impact factor: 6.875
  7 in total
  4 in total

Review 1.  Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.

Authors:  Maria Angeles Martinez-Grau; Maria Alvim-Gaston
Journal:  Pharmaceut Med       Date:  2019-06

2.  Establishing a reliable framework for harnessing the creative power of the scientific crowd.

Authors:  Adrian J Carter; Amy Donner; Wen Hwa Lee; Chas Bountra
Journal:  PLoS Biol       Date:  2017-02-15       Impact factor: 8.029

Review 3.  Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?

Authors:  Alexander Schuhmacher; Oliver Gassmann; Nigel McCracken; Markus Hinder
Journal:  J Transl Med       Date:  2018-05-08       Impact factor: 5.531

4.  International ethics harmonization and the global alliance for genomics and health.

Authors:  Bartha M Knoppers
Journal:  Genome Med       Date:  2014-02-27       Impact factor: 11.117
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.